MicroRNA‑195 suppresses rectal cancer growth and metastasis via regulation of the PI3K/AKT signaling pathway

Wang,Yeli; Mu,Linsong; Huang,Miaoling

doi:10.3892/mmr.2019.10717

MicroRNA‑195 suppresses rectal cancer growth and metastasis via regulation of the PI3K/AKT signaling pathway

Authors:
- Yeli Wang
- Linsong Mu
- Miaoling Huang
View Affiliations

Affiliations: Department of Anorectal, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China, Department of General Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: October 1, 2019 https://doi.org/10.3892/mmr.2019.10717
Pages: 4449-4458
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) play a vital role in the progression of cancer, however, only limited data on miRNAs in rectal cancer are available. The aim of the present study was to investigate whether miR‑195 could inhibit the progression of rectal cancer. The miR‑195 mimic was transfected into 2 types of human rectal cancer cells (SW837 and SW1463). Cell viability and apoptosis were analyzed by Cell Counting Kit‑8 (CCK‑8) assay and flow cytometry, and cell migration and invasion were assessed by scratch test and Transwell assay. The results revealed that insulin‑like growth factor 1 (IGF1) was predicted as a potential target of miR‑195 by Targetscan7.2, and the result was verified by dual‑luciferase reporter assay. The co‑transfection of IGF1 was performed to confirm the underlying mechanism of tumor suppressor of miR‑195 in rectal cancer. The activation of PI3K/AKT signaling was determined by western blotting. The levels of miR‑195 in SW837 and SW1463 cells were revealed to be lower than in human rectal mucosa epithelial cells. After the transfection with miR‑195, the cell viability was decreased, while the apoptosis was significantly increased (SW837: 5.21% vs. 20.96%; SW1463: 4.19% vs. 25.22%). Moreover, cell migration and invasion were significantly inhibited in the mimic group. miR‑195 specifically targeted IGF1, however, the co‑transfection of IGF1 could partially reverse the inhibitory effects of miR‑195 on rectal cancer cells. It was also determined that the phosphorylation of PI3K and AKT were significantly inhibited in the mimic group. The tumor suppressive ability of miR‑195 in rectal cancer cell proliferation and metastasis was mediated by blocking IGF1 expression and inhibiting the PI3K/AKT pathway.

View Figures

View References

1	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
2	Slaby O, Svoboda M, Michalek J and Vyzula R: MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
3	Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F and Vandesompele J: A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI
4	Khorasani M, Teimoori-Toolabi L, Farivar TN, Asgari M, Abolhasani M, Shahrokh H, Afgar A, Kalantari E, Peymani A and Mahdian R: Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer. Cancer Biomark. 22:19–28. 2018. View Article : Google Scholar : PubMed/NCBI
5	van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17:212015. View Article : Google Scholar : PubMed/NCBI
6	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ryan BM: microRNAs in Cancer Susceptibility. Adv Cancer Res. 135:151–171. 2017. View Article : Google Scholar : PubMed/NCBI
8	Abba ML, Patil N, Leupold JH, Moniuszko M, Utikal J, Niklinski J and Allgayer H: MicroRNAs as novel targets and tools in cancer therapy. Cancer Lett. 387:84–94. 2017. View Article : Google Scholar : PubMed/NCBI
9	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
11	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhou XG, Huang XL, Liang SY, Tang SM, Wu SK, Huang TT, Mo ZN and Wang QY: Identifying miRNA and gene modules of colon cancer associated with pathological stage by weighted gene co-expression network analysis. Onco Targets Ther. 11:2815–2830. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang W, Sun Z, Su L, Wang F, Jiang Y, Yu D, Zhang F, Sun Z and Liang W: miRNA-185 serves as a prognostic factor and suppresses migration and invasion through Wnt1 in colon cancer. Eur J Pharmacol. 825:75–84. 2018. View Article : Google Scholar : PubMed/NCBI
14	Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer: Differential expression by tumor location and subtype. Genes Chromosomes Cancer. 50:196–206. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cancer Genome Atlas Network, . Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
16	Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, et al: The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Hong S, Yu S, Huang Y, Chen S, Liu Y, Zhang Q, Li Y and Xiao H: MiR-195 inhibits tumor growth and metastasis in papillary thyroid carcinoma cell lines by targeting CCND1 and FGF2. Int J Endocrinol. 2017:61804252017. View Article : Google Scholar : PubMed/NCBI
19	Wang X, Wang Y, Lan H and Li J: MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Du B, Wang X, Wu D, Wang T, Yang X, Wang J, Shi X, Chen L and Zhang W: MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer. Mol Med Rep. 18:1909–1916. 2018.PubMed/NCBI
22	Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G and Kerin MJ: miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis. 28:247–260. 2013. View Article : Google Scholar : PubMed/NCBI
23	Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and Qian B: MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget. 6:9445–9456. 2015.PubMed/NCBI
24	Shen CJ, Cheng YM and Wang CL: LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target. 25:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
25	Qattan A, Intabli H, Alkhayal W, Eltabache C, Tweigieri T and Amer SB: Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. BMC Cancer. 17:7992017. View Article : Google Scholar : PubMed/NCBI
26	Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yan JJ, Chang Y, Zhang YN, Lin JS, He XX and Huang HJ: miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. Oncol Lett. 13:3118–3126. 2017. View Article : Google Scholar : PubMed/NCBI
28	Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, Nan KJ and Han LL: MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 8:99757–99771. 2017.PubMed/NCBI
29	Chen H, Wang J, Hu B, Wu X, Chen Y, Li R and Yuan W: MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2. Mol Cell Biochem. 406:21–30. 2015. View Article : Google Scholar : PubMed/NCBI
30	Weroha SJ and Haluska P: The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 41:335–350. 2012. View Article : Google Scholar : PubMed/NCBI
31	De Santi M, Annibalini G, Barbieri E, Villarini A, Vallorani L, Contarelli S, Berrino F, Stocchi V and Brandi G: Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor. Cell Oncol (Dordr). 39:149–159. 2016. View Article : Google Scholar : PubMed/NCBI
32	Shafiee MN, Seedhouse C, Mongan N, Chapman C, Deen S, Abu J and Atiomo W: Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer. Mol Cell Endocrinol. 424:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
33	Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN and Le Marchand L: Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 21:810–820. 2012. View Article : Google Scholar : PubMed/NCBI
34	Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H, Zhou M, Pan C, Zhang J, Huang N, et al: IGF1/IGF1R/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
35	Xie Y and Liu L: Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. Oncology Lett. 16:5615–5620. 2018.
36	Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
37	Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 210:767–776, 776–778. 2010. View Article : Google Scholar : PubMed/NCBI
38	Rychahou PG, Murillo CA and Evers BM: Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery. 138:391–397. 2005. View Article : Google Scholar : PubMed/NCBI